Service Line:+1-315-239-3085
Address:FL-4, Building A5, International Enterprise Community, Tianjin, China
Email:info@kmdbioscience.com
Catalog Number | YR1539 |
---|---|
Product Name | Anti-Human Ganglioside GD2 Recombinant Antibody(Naxitamab) |
Molecular Name | Naxitamab |
Alias | Anti-Ganglioside GD2 Recombinant Antibody, Research Grade Naxitamab |
CAS Number | 1879925-92-4 |
Target | Ganglioside GD2[Homo sapiens] |
Isotype | IgG1 Kappa |
Clonity | Monoclonal |
Source | CHO Cells |
Size | 1mg, 5mg |
Concentration | 1mg/ml |
Purity | >95% as determined by SDS-PAGE |
Buffer | PBS, pH7.5 |
Background | Naxitamab, sold under the brand name Danyelza, is an anti-cancer medication. It is a monoclonal antibody used in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) for people one year of age and older with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow demonstrating a partial response, minor response, or stable disease to prior therapy. |
Storage | It is recommended to aliquote and store at -20°C for long term storage. Avoid repeated freezing and thawing cycles. |
Note | This product is for research use only. |